Instrument Inactif

Autres langues Freeline Therapeutics Holdings plc

Actions

FRLN

US35655L2060

Autres langues

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Freeline Therapeutics Announces New Name and Brand	17/06
Freeline Therapeutics Holdings plc acquired SwanBio Therapeutics, Inc. from Mass General Brigham Ventures, LLC, Syncona Investment Management Limited and Syncona Partners LLP.	17/06
Freeline Presents Positive New Data from Phase 1/2 Trial of FLT201, Its Novel Gene Therapy Candidate for Gaucher Disease, in Late-Breaking Oral Presentation at ASGCT 27th Annual Meeting	09/05
Freeline to Present New Data on its Gaucher and Parkinson’s Disease Programs at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting	24/04
Syncona’s Takeover of Freeline Therapeutics Becomes Effective	20/02
Freeline Therapeutics Holdings plc Announces Resignation of Julia Gregory, Martin Andrews, Jeffrey Chodakewitz, Colin Love and Paul Schneider from the Board	20/02
Acquisition of Freeline by Syncona Becomes Effective	20/02
Freeline Therapeutics Holdings plc(NasdaqCM:FRLN) dropped from NASDAQ Composite Index	20/02
Syncona Investment Management Limited completed the acquisition of the remaining 42.08% stake in Freeline Therapeutics Holdings plc.	20/02
Freeline shareholders approve Syncona acquisition	12/02
Freeline Therapeutics' Shareholders Approve Acquisition by Syncona	12/02
Freeline Shareholders Approve Acquisition by Syncona	12/02
Syncona says Freeline trial for Gaucher disease treatment positive	19/01
European Equities Traded in the US as American Depositary Receipts Gain Friday	22/12
Pharma und Gesundheit: weitere Konsolidierung	13/12
Farma en gezondheid: consolidatie gaat door	12/12
Farmaceutica e salute: continua il consolidamento	11/12
Farmacia y salud: La consolidación continúa	11/12
Hemophilia Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023 \| Centessa Pharmaceuticals, Alnylam Pharmaceuticals, ASC Therapeutics, Spark Therapeutics, Freeline Therapeutics	08/12
Freeline Therapeutics : Reports Second Quarter 2023 Financial Results and Business Highlights - Form 6-K	01/12

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Freeline Therapeutics Holdings plc

Actions

FRLN

US35655L2060

Autres langues

Filtres